XTL Biopharmaceuticals Ltd. NCM · XTLB
Price alert —
Sign in to get a one-time email the moment XTLB crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · XTLB
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2024-12-31 | $0.0B | $-0.0B | $-0.0B | — | -88.2% | -281.0% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare XTLB vs peers
Line XTLB up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with XTLB
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 0 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
No earnings history available.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| XTLB ★ | $0B | — | — | — | -5.5 | — | — | — | — | -30.32% |
| LLY | $1,051B | 41.8 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 32.1 | 19.2 | 0.9 | 17.7 | 4.0 | 19.5% | 0.4% | 61.5% | 5.88% |
| JNJ | $609B | 29.3 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.2 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 2.97%
| Holder | Shares | % out |
|---|---|---|
| Noked Israel Ltd. | 49,722 | 2.10% |
| Smartharvest Portfolios, LLC | 13,351 | 0.56% |
| Rhumbline Advisers | 5,987 | 0.25% |
| Gamma Investing LLC | 1,213 | 0.05% |
| Tower Research Capital LLC (TRC) | 244 | 0.01% |
| Morgan Stanley | 10 | — |
Insider activity · 90d
No insider trades for XTLB in last 90d.
Analyst estimates
yfinanceWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
Consensus: none (mean None). Distribution requires FINNHUB_API_KEY.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2008-12-03 | Insider transaction (Form 4) | view · |
| 4 | 2008-11-04 | Insider transaction (Form 4) | view · |
| 4 | 2008-11-04 | Insider transaction (Form 4) | view · |
| 4 | 2008-06-19 | Insider transaction (Form 4) | view · |
| 4 | 2008-06-11 | Insider transaction (Form 4) | view · |
| 4 | 2008-06-06 | Insider transaction (Form 4) | view · |
| 4 | 2008-05-06 | Insider transaction (Form 4) | view · |
| 4 | 2008-05-02 | Insider transaction (Form 4) | view · |
| 4 | 2008-04-16 | Insider transaction (Form 4) | view · |
| 4 | 2008-04-04 | Insider transaction (Form 4) | view · |
| 4 | 2008-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2008-03-20 | Insider transaction (Form 4) | view · |
| 4 | 2008-03-19 | Insider transaction (Form 4) | view · |
| 4 | 2008-03-19 | Insider transaction (Form 4) | view · |
| 4 | 2008-03-10 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-29 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-28 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-28 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-22 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-19 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-08 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-06 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-05 | Insider transaction (Form 4) | view · |
| 4 | 2008-02-01 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-30 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-29 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-28 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-25 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-18 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-15 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-11 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-08 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-04 | Insider transaction (Form 4) | view · |
| 4 | 2008-01-02 | FORM 4 | view · |
| 4 | 2007-12-31 | Insider transaction (Form 4) | view · |
| 4 | 2007-08-21 | Insider transaction (Form 4) | view · |
| 4 | 2006-08-28 | Insider transaction (Form 4) | view · |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Options picks · XTLB
ITM + OTM ideas from the latest scanLoading…
Congress trades · XTLB
STOCK Act disclosuresLoading…
SEC filings & insiders · XTLB
EDGAR · liveLoading…
Holders · XTLB
Institutions & insider activityLoading…